3:19 PM
Sep 13, 2018
 |  BC Extra  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care.

The China and emerging markets unit will be led by Olivier Charmeil, who is head of the pharma’s general medicines and emerging markets (GEM) unit.

China is Sanofi’s second-largest market behind the U.S. The pharma established a China unit headquartered in Shanghai in 1982, and just this July launched a global R&D operations hub in Chengdu with a €66 million ($77 million) investment to support clinical R&D.

The newly formed primary care unit will combine the product portfolios of Sanofi's diabetes and cardiovascular (DCV) unit with its established products unit (currently part of the GEM unit). It will exclusively focus on mature markets.

Sanofi has hired Dieter Weinand from Bayer AG (Xetra:BAYN) to lead the unit as EVP, effective Nov. 1. Meanwhile, Stefan Oelrich, Sanofi’s DCV head, will leave Sanofi and go to Bayer, where he’ll replace Weinand as head of the pharmaceuticals division.

Sanofi said its remaining global business units will remain unchanged.

The move is the latest step in CEO Olivier Brandicourt’s plan to return the company to growth by 2020. Brandicourt became Sanofi’s CEO in April 2015 after Christopher Viehbacher’s ouster in the wake of flagging diabetes sales and moribund EPS performance. His goal has been to get the pharma to and maintain positive EPS, replace declining Lantus insulin glargine revenues, and focus the company on disease areas and businesses where it could be a top-three company (see “Growing Up Genzyme”).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD